PCN139 Cost per Consequence Analysis of Erdafinitib and ANTI-PD1/PDL1 Therapies for Metastatic Urothelial Carcinoma FGFR+ from the Perspective of Brazilian Private Health SystemP. Souza, J. Lancheros,L. Souza, A. PiedadeValue in Health（2020）引用 1|浏览6暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
